AIMS: We performed the retrospective analysis to clarify the significance of drug monitoring for mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), in prophylaxis for graft-vs-host disease (GVHD) in cord blood transplantation. METHODS: We retrospectively analysed the data of 46 patients who underwent first cord blood transplantation and received GVHD prophylaxis with tacrolimus plus MMF. MPA levels were measured on days 7 and 21, and 24-hour areas under the curve (AUC0-24 ) were estimated. RESULTS: The engraftment and 3-year overall survival rates of all patients were 94% and 78%, respectively. The cumulative incidence of sepsis before engraftment was higher in patients with AUC0-24 on day 7 of >60 μg h/mL than in other patients (33 vs 6%, P = .02). The cumulative incidence of grade II-IV acute GVHD was higher in patients with AUC0-24 on day 21 of ≤30 μg h/mL than in other patients (80 vs 50%, P = .04). The cumulative incidence of human herpesvirus 6 reactivation was higher in patients with AUC0-24 on day 21 of ≤48 μg h/mL (median) than in other patients (50 vs 19%, P = .03). CONCLUSION: Blood level of MPA was associated with risk of acute GVHD and infection. A prospective trial evaluating the benefit of personalized MMF dosing using MPA levels is needed.
AIMS: We performed the retrospective analysis to clarify the significance of drug monitoring for mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), in prophylaxis for graft-vs-host disease (GVHD) in cord blood transplantation. METHODS: We retrospectively analysed the data of 46 patients who underwent first cord blood transplantation and received GVHD prophylaxis with tacrolimus plus MMF. MPA levels were measured on days 7 and 21, and 24-hour areas under the curve (AUC0-24 ) were estimated. RESULTS: The engraftment and 3-year overall survival rates of all patients were 94% and 78%, respectively. The cumulative incidence of sepsis before engraftment was higher in patients with AUC0-24 on day 7 of >60 μg h/mL than in other patients (33 vs 6%, P = .02). The cumulative incidence of grade II-IV acute GVHD was higher in patients with AUC0-24 on day 21 of ≤30 μg h/mL than in other patients (80 vs 50%, P = .04). The cumulative incidence of human herpesvirus 6 reactivation was higher in patients with AUC0-24 on day 21 of ≤48 μg h/mL (median) than in other patients (50 vs 19%, P = .03). CONCLUSION: Blood level of MPA was associated with risk of acute GVHD and infection. A prospective trial evaluating the benefit of personalized MMF dosing using MPA levels is needed.
Authors: Dirk R J Kuypers; Yannick Le Meur; Marcelo Cantarovich; Michael J Tredger; Susan E Tett; Dario Cattaneo; Burkhard Tönshoff; David W Holt; Jeremy Chapman; Teun van Gelder Journal: Clin J Am Soc Nephrol Date: 2010-01-07 Impact factor: 8.237
Authors: P Ljungman; J Aschan; I Lewensohn-Fuchs; S Carlens; K Larsson; B Lönnqvist; J Mattsson; E Sparrelid; J Winiarski; O Ringdén Journal: Transplantation Date: 1998-11-27 Impact factor: 4.939
Authors: I Haentzschel; J Freiberg-Richter; U Platzbecker; A Kiani; J Schetelig; T Illmer; G Ehninger; E Schleyer; M Bornhäuser Journal: Bone Marrow Transplant Date: 2008-03-24 Impact factor: 5.483
Authors: Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz Journal: Biol Blood Marrow Transplant Date: 2009-09-01 Impact factor: 5.742
Authors: Reinier M van Hest; Jeanette K Doorduijn; Brenda C M de Winter; Jan J Cornelissen; Arnold G Vulto; Michael Oellerich; Bob Löwenberg; Ron A A Mathot; Victor William Armstrong; Teun van Gelder Journal: Ther Drug Monit Date: 2007-06 Impact factor: 3.681
Authors: R Storb; H J Deeg; M Pepe; F Appelbaum; C Anasetti; P Beatty; W Bensinger; R Berenson; C D Buckner; R Clift Journal: Blood Date: 1989-05-01 Impact factor: 22.113